KEGG   DRUG: Secukinumab
Entry
D09967                      Drug                                   
Name
Secukinumab (USAN/INN);
Secukinumab (genetical recombination) (JAN);
Cosentyx (TN)
Product
COSENTYX (Novartis Pharmaceuticals Corporation)
Formula
C6584H10134N1754O2042S44
Exact mass
147851.0774
Mol weight
147942.2994
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWMNWVRQA PGKGLEWVAA INQDGSEKYY
VGSVKGRFTI SRDNAKNSLY LQMNSLRVED TAVYYCVRDY YDILTDYYIH YWYFDLWGRG
TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF
PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP
APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL
TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK
(Light chain)
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY GASSRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPCTFG QGTRLEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(Disulfide bridge: H22-H96, H154-H210, H271-H331, H377-H435, H236-H'236, H239-H'239, L23-L89, L135-L195, H230-L215)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
Therapeutic category: 3999
ATC code: L04AC10
Product: D09967<JP/US>
Efficacy
Antipsoriatic, Anti-IL-17A antibody
  Disease
Plaque psoriasis [DS:H01656]
Psoriatic arthritis [DS:H01507]
Ankylosing spondylitis [DS:H01674]
  Type
Monoclonal antibody
Target
IL17A [HSA:3605] [KO:K05489]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa05323  Rheumatoid arthritis
Interaction
Structure map
map07050  Antirheumatics - DMARDs and biological agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC10 Secukinumab
      D09967  Secukinumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Interleukin Blockers
    Secukinumab
     D09967  Secukinumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D09967  Secukinumab (USAN/INN); Secukinumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D09967  Secukinumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D09967  Secukinumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL17A
     D09967  Secukinumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09967
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09967
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09967
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09967
Other DBs
CAS: 1229022-83-6
PubChem: 124490635
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system